CNTN

CNTN is not an operating business in any conventional sense. Per its own MD&A, the company "has not recognized revenue since inception or for the years ended December 31, 2025 and 2024," and in February 2026 it rebranded from a biotech (HSB-1216 "deprioritized"; R&D cut 51.9% to $3.07M) into Canton Strategic Holdings, whose "principal treasury and operational strategy" is acquiring and holding Canton Coin (CC) and running validators. The 10-K frames this as "a fundamental change in our risk profile," and it is: there is no revenue engine, only a wager on a novel digital asset.

The balance sheet looks superficially strong — $519M total assets, $398M equity, liabilities/equity just 0.30x — but this is an artifact of the pivot, not value creation. Assets grew 13,849% and equity grew 30,331% in one year while shares outstanding exploded 2,587% to 56.7M via a November 2025 private placement, an ATM program, a shelf, and a January 2026 registered direct offering with pre-funded warrants. So the ~$400M of equity is overwhelmingly a pile of illiquid CC tokens funded by relentless dilution — not retained profits (accumulated deficit is -$72.8M). Actual cash is only $17.0M against a -$16.1M operating cash burn, meaning roughly a year of runway before more dilution is required.